Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 360 entries
View as:

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Phase: N/A Priority: Normal
NCT ID: NCT00700310 Org: User:
Start: 08/31/08 End: 01/31/10 Due: 01/31/11

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02873156 Org: User:
Start: 08/10/16 End: 11/29/17 Due: 11/29/18

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

Phase: N/A Priority: Normal
NCT ID: NCT01161524 Org: User:
Start: 09/30/10 End: 11/30/14 Due: 11/30/15

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00413192 Org: User:
Start: 01/31/07 End: 02/28/13 Due: 02/28/14

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00278993 Org: User:
Start: 01/31/06 End: 01/31/08 Due: 01/31/09

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01673451 Org: User:
Start: 08/31/12 End: 07/31/13 Due: 07/31/14

2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD

Phase: N/A Priority: Normal
NCT ID: NCT00209508 Org: User:
Start: 11/30/02 End: 10/31/05 Due: 10/31/06

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Phase: N/A Priority: Normal
NCT ID: NCT00236197 Org: User:
Start: 10/31/05 End: 06/30/08 Due: 06/30/09

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

Phase: N/A Priority: Normal
NCT ID: NCT01877083 Org: User:
Start: 04/05/13 End: 11/02/17 Due: 11/02/18

Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00525590 Org: User:
Start: 12/12/07 End: 12/01/10 Due: 12/01/11

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Phase: N/A Priority: Normal
NCT ID: NCT03338296 Org: User:
Start: 09/28/17 End: 04/03/20 Due: 04/03/21

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT02398669 Org: User:
Start: 03/31/15 End: 05/31/15 Due: 05/31/16

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00539929 Org: User:
Start: 09/30/07 End: 07/31/08 Due: 07/31/09

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01605162 Org: User:
Start: 05/31/12 End: 02/28/14 Due: 02/28/15

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Phase: N/A Priority: Normal
NCT ID: NCT02657369 Org: User:
Start: 07/07/16 End: 09/26/18 Due: 09/26/19

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

Phase: N/A Priority: Normal
NCT ID: NCT06462404 Org: User:
Start: 06/20/24 End: 03/17/25 Due: 03/17/26

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00566501 Org: User:
Start: 12/14/07 End: 04/01/10 Due: 04/01/11

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

Phase: N/A Priority: Normal
NCT ID: NCT05745207 Org: User:
Start: 02/20/23 End: 01/18/24 Due: 01/18/25

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05726851 Org: User:
Start: 02/06/23 End: 01/30/24 Due: 01/30/25

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03887455 Org: User:
Start: 03/27/19 End: 09/15/27 Due: 09/15/28

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03386942 Org: User:
Start: 11/28/17 End: 10/26/22 Due: 10/26/23

Study of E7046 in Subjects With Selected Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02540291 Org: User:
Start: 07/30/15 End: 02/27/18 Due: 02/27/19

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04547361 Org: User:
Start: 09/14/20 End: 05/26/21 Due: 05/26/22

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00124527 Org: User:
Start: 03/31/05 End: 08/31/06 Due: 08/31/07

Study of Lemborexant-Alcohol Interaction in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03483636 Org: User:
Start: 03/12/18 End: 09/12/18 Due: 09/12/19